---
id: trypanosomiasis_098
category: organisms
tags: [trypanosomiasis, Chagas-disease, African-sleeping-sickness, Trypanosoma-cruzi]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Trypanosomiasis (Chagas Disease & African Sleeping Sickness)

**Q:** What are the clinical features, diagnosis, and treatment of American trypanosomiasis (Chagas disease) vs African trypanosomiasis (sleeping sickness)?

**A:**

## OVERVIEW: TWO DISEASES

| **Feature** | **American Trypanosomiasis (Chagas)** | **African Trypanosomiasis (Sleeping Sickness)** |
|-------------|---------------------------------------|--------------------------------------------------|
| **Organism** | ***Trypanosoma cruzi*** | ***T. brucei gambiense*** (West Africa - 98%)<br>***T. brucei rhodesiense*** (East Africa - 2%) |
| **Vector** | **Triatomine bug** ("kissing bug") - feces | **Tsetse fly** (*Glossina* species) - bite |
| **Geographic Distribution** | **Latin America** (Mexico to Argentina) | **Sub-Saharan Africa** (36 countries) |
| **Clinical Phases** | Acute → Indeterminate → Chronic (cardiomyopathy, megasyndromes) | Stage 1 (hemolymphatic) → Stage 2 (meningoencephalitic) |
| **Main Complication** | **Cardiomyopathy** (30%), megacolon/megaesophagus | **Meningoencephalitis** (fatal if untreated) |
| **Treatment** | Benznidazole, nifurtimox | Fexinidazole, eflornithine, melarsoprol |

---

## 1. AMERICAN TRYPANOSOMIASIS (CHAGAS DISEASE)

**Organism:** *Trypanosoma cruzi* (flagellated protozoan)

**Vector:** **Triatomine bug** ("kissing bug", "assassin bug", "vinchuca")
- **Transmission:** Bug defecates while feeding → Parasite in feces enters through bite wound or mucosa (conjunctiva)

**Other Transmission:**
- **Blood transfusion** (screened in US since 2007)
- **Organ transplantation**
- **Congenital** (vertical transmission)
- **Oral** (contaminated food/drinks - acai berry juice outbreaks)

**Epidemiology:**
- **~6 million infected** worldwide (Latin America)
- **~300,000 infected** in US (mostly immigrants from endemic areas)

---

### **Clinical Phases:**

---

#### **A. Acute Phase (2-3 months):**

**Clinical Features:**
- **Most asymptomatic** (70-90%)
- **Fever, malaise, lymphadenopathy, hepatosplenomegaly**
- **Romaña sign:** Unilateral painless periorbital edema + conjunctivitis (inoculation via conjunctiva)
- **Chagoma:** Indurated skin nodule at bite site
- **Severe cases (<1%):** Myocarditis, meningoencephalitis (often fatal in children)

**Diagnosis:**
- **Blood smear (Giemsa stain):** Visualize **trypomastigotes** (high parasitemia in acute phase)
- **PCR** (most sensitive)

**Key Point:** **Romaña sign = Chagas** (unilateral periorbital edema from conjunctival inoculation)

---

#### **B. Indeterminate Phase (10-30 years):**

**Clinical Features:**
- **Asymptomatic** (positive serology, no organ damage)
- **60-70% remain indeterminate** for life

**Diagnosis:**
- **Serology positive** (IgG antibodies)
- **Microscopy negative** (low parasitemia)

---

#### **C. Chronic Phase (30-40% Progress):**

**Clinical Manifestations:**

---

##### **1. Chronic Chagas Cardiomyopathy (Most Common - 30%):**

**Pathophysiology:**
- **Myocardial inflammation → Fibrosis** (direct parasite damage + immune-mediated)
- **Conduction system damage** (AV block, RBBB, ventricular arrhythmias)

**Clinical Features:**
- **Dilated cardiomyopathy** (biventricular dysfunction)
- **Arrhythmias:** Ventricular tachycardia (VT), complete heart block, atrial fibrillation
- **Heart failure** (NYHA III-IV)
- **Thromboembolism** (apical aneurysm → mural thrombus)
- **Sudden cardiac death** (ventricular arrhythmias)

**Characteristic Findings:**
- **Apical aneurysm** (pathognomonic - thin, dyskinetic apex on echo/MRI)
- **Right bundle branch block (RBBB) + left anterior fascicular block (LAFB)** = classic ECG
- **Segmental wall motion abnormalities** (not following coronary distribution)

**Key Point:** **Chagas cardiomyopathy = apical aneurysm + RBBB + LAFB** (ECG pattern)

---

**Treatment (Heart Failure):**
- **Standard heart failure therapy:**
  - **ACE inhibitors/ARBs** (reduce mortality if LVEF <45%)
  - **Beta-blockers** (carvedilol preferred)
  - **Spironolactone/eplerenone** (if LVEF <35% + NYHA III-IV)
  - **Diuretics, digoxin**
- **Implantable cardioverter-defibrillator (ICD):** For secondary prevention (VT/VF survivors)
- **Cardiac resynchronization therapy (CRT):** If LBBB + QRS >150 ms + LVEF <35%
- **Heart transplantation:** Refractory heart failure

**Antiparasitic Treatment:**
- **BENEFIT Trial (2015):** Benznidazole did NOT reduce cardiac clinical deterioration in established cardiomyopathy
- **Recommendation:** Consider benznidazole for **early/mild cardiomyopathy** (may slow progression), but NOT indicated for advanced cardiomyopathy

---

##### **2. Megasyndromes (10%):**

**Pathophysiology:**
- **Destruction of enteric neurons** (Auerbach plexus) → Aperistalsis, dilation

**Clinical Syndromes:**

**Megaesophagus:**
- **Dysphagia, regurgitation, chest pain**
- **Aspiration pneumonia**
- **Barium swallow:** Dilated esophagus with "bird beak" narrowing at GE junction (mimics achalasia)

**Megacolon:**
- **Constipation, abdominal distension, fecal impaction**
- **Volvulus, perforation** (life-threatening)

**Treatment:**
- **Megaesophagus:** Pneumatic dilation OR **Heller myotomy**
- **Megacolon:** **Surgical resection** (Duhamel/Haddad procedure)

**Key Point:** **Megasyndromes = enteric neuron destruction** (megaesophagus, megacolon)

---

### **Diagnosis:**

**Acute Phase:**
- **Microscopy:** Blood smear (Giemsa) → Visualize trypomastigotes
- **PCR** (most sensitive)

**Chronic Phase:**
- **Serology:** **≥2 positive tests** required (ELISA, IFA, or other)
  - **IgG antibodies** (anti-*T. cruzi*)
- **Use 2 tests** (different methods) due to cross-reactivity risk

**Key Point:** **Chronic Chagas = ≥2 positive serologies** (no parasites on smear - low parasitemia)

---

### **Treatment:**

**Antiparasitic Therapy:**

| **Agent** | **Dosing** | **Duration** | **FDA Approval** |
|-----------|------------|--------------|------------------|
| **Benznidazole** | **5-7 mg/kg/day PO divided BID** (max 300 mg/day) | **60 days** | **FDA-approved** (pediatric 2-12 years) |
| **Nifurtimox** | **8-10 mg/kg/day PO divided TID** | **60-90 days** | **FDA-approved** (pediatric 0-18 years) |

**Indications for Treatment:**

| **Population** | **Recommendation** |
|----------------|---------------------|
| **Acute Chagas** | **Always treat** (high cure rate >80%) |
| **Congenital Chagas** | **Always treat** (high cure rate) |
| **Children/adolescents (chronic)** | **Always treat** |
| **Adults <50 years (chronic, no advanced cardiomyopathy)** | **Strongly recommended** (may prevent progression) |
| **Adults >50 years (chronic)** | **Individualize** (weigh benefits vs adverse effects) |
| **Advanced Chagas cardiomyopathy** | **NOT indicated** (BENEFIT trial - no benefit) |
| **Reactivation (immunosuppressed, HIV)** | **Always treat** |

**Key Point:** **Benznidazole = first-line** (acute, children, adults <50 without advanced cardiomyopathy)

---

**Adverse Effects:**

**Benznidazole:**
- **Rash** (30-50%)
- **Peripheral neuropathy** (10-30%)
- **Bone marrow suppression** (leukopenia)
- **GI upset**

**Nifurtimox:**
- **GI upset** (nausea, vomiting, anorexia) - 70%
- **Neuropsychiatric** (insomnia, tremor, paresthesias)
- **Weight loss**

**Contraindications:**
- **Pregnancy** (both drugs)
- **Severe renal/hepatic impairment**
- **Nifurtimox:** Neurologic/psychiatric disorders

---

### **Prevention:**

**Vector Control:**
- **Indoor residual spraying** (insecticides)
- **Improved housing** (plastered walls, roofs to prevent bug infestation)

**Screening:**
- **Blood donor screening** (US since 2007)
- **Organ donor screening**
- **Pregnant women** (endemic countries + US immigrants)

---

## 2. AFRICAN TRYPANOSOMIASIS (SLEEPING SICKNESS)

**Organism:**
- ***T. brucei gambiense*** (West/Central Africa - 98% of cases) - chronic (months to years)
- ***T. brucei rhodesiense*** (East Africa - 2% of cases) - acute (weeks to months)

**Vector:** **Tsetse fly** (*Glossina* species) - Parasite transmitted via **fly bite**

**Epidemiology:**
- **~1,000 cases/year** reported (WHO goal: elimination by 2030)
- **Rural sub-Saharan Africa**

---

### **Clinical Phases:**

---

#### **Stage 1: Hemolymphatic (Early) - Weeks to Months:**

**Clinical Features:**
- **Trypanosomal chancre:** Painful nodule at bite site (appears 1-2 weeks post-bite)
- **Fever** (intermittent, "Winterbottom sign" - posterior cervical lymphadenopathy in gambiense)
- **Headache, myalgias**
- **Lymphadenopathy** (posterior cervical in gambiense)
- **Hepatosplenomegaly**
- **Rash** (circinate erythema)

**Key Point:** **Winterbottom sign** = posterior cervical lymphadenopathy (T. b. gambiense)

---

#### **Stage 2: Meningoencephalitic (Late) - Fatal if Untreated:**

**Clinical Features:**
- **Progressive neurologic decline:**
  - **Sleep disturbances** (daytime somnolence, nocturnal insomnia) → "sleeping sickness"
  - **Behavioral changes** (irritability, aggression, psychosis)
  - **Movement disorders** (tremor, ataxia, seizures)
  - **Coma** (if untreated)
- **Fatal if untreated**

**Key Point:** **Stage 2 = CNS involvement** (sleep disturbances, neuropsychiatric symptoms)

---

### **Diagnosis:**

**Microscopy:**
- **Blood smear** (Giemsa) → Visualize **trypomastigotes** (high parasitemia in rhodesiense)
- **Lymph node aspirate** (gambiense)
- **Chancre fluid** (early infection)

**Lumbar Puncture (Stage Determination):**
- **Stage 1:** CSF WBC ≤5 cells/μL, NO trypanosomes
- **Stage 2:** CSF WBC >5 cells/μL OR trypanosomes present in CSF

**PCR:** Available (reference labs)

**Key Point:** **LP essential for staging** (Stage 1 vs Stage 2 determines treatment)

---

### **Treatment:**

**Treatment by Stage & Species:**

---

#### ***T. brucei gambiense* (West Africa):**

| **Stage** | **First-Line** | **Dosing** | **Duration** |
|-----------|----------------|------------|--------------|
| **Stage 1** | **Pentamidine** | **4 mg/kg IM/IV daily** | **7 days** |
| **Stage 2** | **Fexinidazole** (oral - WHO 2024 preferred) | **Loading:** 1800 mg PO daily x 4 days<br>**Maintenance:** 1200 mg PO daily x 6 days | **10 days** |
| **Stage 2 (alternative)** | **Eflornithine** + **Nifurtimox (NECT)** | Eflornithine 400 mg/kg/day IV divided q6h x 7 days + Nifurtimox 15 mg/kg/day PO divided TID x 10 days | **7-10 days** |

**Key Point:** **Fexinidazole = oral, first-line** for Stage 2 gambiense (WHO 2024)

---

#### ***T. brucei rhodesiense* (East Africa):**

| **Stage** | **First-Line** | **Dosing** | **Duration** |
|-----------|----------------|------------|--------------|
| **Stage 1** | **Fexinidazole** (WHO 2024 update) | **Same as gambiense** | **10 days** |
| **Stage 1 (children <6 years or <20 kg)** | **Suramin** | **Test dose:** 100-200 mg IV<br>**THEN:** 20 mg/kg IV weekly | **5 weeks** |
| **Stage 2** | **Fexinidazole** (WHO 2024 update) | **Same as gambiense** | **10 days** |
| **Stage 2 (children <6 years or <20 kg)** | **Melarsoprol** | **2-3.6 mg/kg IV daily** (gradual increase) | **10 days** |

**Key Point:** **Fexinidazole now first-line** for rhodesiense (WHO 2024 update)

---

**Alternative (Historical):**

**Melarsoprol:**
- **Arsenic-based drug** (highly toxic)
- **Encephalopathic syndrome:** 5-10% (case-fatality 50% if occurs)
- **Reserved for:** Stage 2 rhodesiense when fexinidazole unavailable

**Eflornithine:**
- **NOT effective** for rhodesiense (only gambiense)

---

### **Prognosis:**

**Stage 1:**
- **High cure rate** with treatment

**Stage 2:**
- **Good outcomes with fexinidazole/eflornithine**
- **Melarsoprol:** High risk of neurologic sequelae (5-10% encephalopathy)
- **Fatal if untreated**

---

## COMPARISON TABLE

| **Feature** | **Chagas Disease** | **African Trypanosomiasis** |
|-------------|-------------------|------------------------------|
| **Acute phase** | Often asymptomatic, Romaña sign | Trypanosomal chancre, fever, Winterbottom sign (gambiense) |
| **Chronic phase** | Cardiomyopathy (30%), megasyndromes (10%) | Meningoencephalitis (sleeping sickness) |
| **Diagnosis (chronic)** | ≥2 positive serologies | Blood smear + LP for staging |
| **Treatment (acute)** | Benznidazole, nifurtimox | Pentamidine (Stage 1), fexinidazole (Stage 2) |
| **Treatment (chronic)** | Benznidazole (if early/no advanced cardiomyopathy) | Fexinidazole, eflornithine+nifurtimox (NECT) |
| **Prognosis** | Cardiomyopathy = leading cause of death | Stage 2 = fatal if untreated |

---

**Mnemonic: "Romaña Sign = Chagas (Periorbital Edema)"**
- **R**omaña sign = unilateral periorbital edema + conjunctivitis
- **C**hagas (T. cruzi) via triatomine bug feces

**Mnemonic: "Winterbottom Sign = African Sleeping Sickness"**
- **W**interbottom sign = posterior cervical lymphadenopathy
- **T. b. gambiense** (West Africa)

**Mnemonic: "Chagas Cardiac Triad = Apical Aneurysm + RBBB + LAFB"**
- **C**hagas cardiomyopathy
- **A**pical aneurysm (pathognomonic)
- **R**BBB + **L**AFB (classic ECG)

**Mnemonic: "African Tryp = LP for Staging (Stage 1 vs 2)"**
- **L**P essential
- **S**tage 1 (hemolymphatic) vs **S**tage 2 (CNS)
- Treatment depends on stage

**Clinical Pearls:**
- **Chagas disease:** Triatomine bug feces (NOT bite), Romaña sign (periorbital edema), cardiomyopathy (apical aneurysm + RBBB + LAFB)
- **BENEFIT trial:** Benznidazole did NOT reduce cardiac deterioration in established cardiomyopathy
- **Treat Chagas if:** Acute, congenital, children, adults <50 without advanced cardiomyopathy
- **Chronic Chagas diagnosis:** ≥2 positive serologies (low parasitemia)
- **African sleeping sickness:** Tsetse fly bite, Winterbottom sign (posterior cervical LAD in gambiense)
- **Stage 2 sleeping sickness:** Sleep disturbances, neuropsychiatric symptoms (fatal if untreated)
- **LP essential** for staging (CSF WBC >5 or trypanosomes = Stage 2)
- **Fexinidazole = oral, first-line** for Stage 2 gambiense and now rhodesiense (WHO 2024)
- **NECT (eflornithine + nifurtimox):** Alternative for gambiense Stage 2
- **Melarsoprol:** Reserved for rhodesiense Stage 2 (children <6 years or fexinidazole unavailable) - high toxicity (encephalopathy 5-10%)

**Media:** None

**Sources:** [CDC 2024 - Chagas disease clinical care], [CDC Yellow Book 2024 - American trypanosomiasis], [AHA 2018 - Chagas cardiomyopathy scientific statement], [BENEFIT Trial 2015 - Benznidazole in chronic Chagas], [WHO 2024 - African trypanosomiasis treatment guidelines], [Lancet Infectious Diseases 2024 - Fexinidazole for rhodesiense HAT], [CDC 2024 - African trypanosomiasis clinical care]
